Biomarker concentration according to HCMV exposure group
| Previous HCMV exposure Median (IQR) | No previous HCMV exposure Median (IQR) | Hodges–Lehmann median difference (95% CI) | p Value | |
|---|---|---|---|---|
| CRP (mg/L) | ||||
| Baseline | 25.4 (10.9–62.3) | 27.9 (11.7–56.8) | −0.5 (−8.2 to 8.2) | 0.83 |
| 3 months | 5.4 (1.7–12.9) | 2.8 (0.81–8.3) | 1.5 (−0.1 to 3.9) | 0.06 |
| HNE (ng/mL) | ||||
| Baseline | 175.2 (133.4–233.7) | 135.0 (108.7–211.6) | 35.8 (14.0 to 58.7) | <0.01 |
| 3 months | 118.1 (95.6–158.2) | 91.3 (76.2–120.4) | 35.8 (13.4 to 41.3) | <0.01 |
| IL-1β (pg/mL) | ||||
| Baseline | 0.0 (0.0–16.5) | 0.0 (0.0–7.1) | 0.0 (0.0 to 0.0) | 0.14 |
| 3 months | 0.0 (0.0–16.0) | 0.0 (0.0–2.5) | 0.0 (0.0 to 0.0) | 0.62 |
| IL-6 (pg/mL) | ||||
| Baseline | 31.1 (8.5–97.6) | 16.4 (6.5–63.5) | 8.1 (0.0 to 20.8) | 0.24 |
| 3 months | 7.1 (0.1–51.2) | 1.5 (0.0–14.3) | 8.1 (0.0 to 20.8) | 0.32 |
| IL-8 (pg/mL) | ||||
| Baseline | 35.8 (14.7–74.0) | 24.4 (11.2–40.2) | 7.5 (−0.6 to 17.2) | 0.07 |
| 3 months | 9.3 (1.9–41.0) | 4.8 (0.3–11.9) | 3.4 (0.0 to 9.5) | 0.16 |
| TGFβ1 (ng/mL) | ||||
| Baseline | 10.7 (7.8–15.3) | 14.3 (10.2–17.8) | −2.4 (−4.1 to −2.4) | 0.03 |
| 3 months | 9.2 (7.5–11.8) | 11.4 (9.8–13.2) | −1.7 (−2.9 to −0.4) | 0.01 |
| SLPI (ng/mL) | ||||
| Baseline | 56.5 (41.4–79.7) | 60.5 (48.2–73.2) | −2.9 (−9.7 to 4.3) | 0.26 |
| 3 months | 46.6 (37.3–63.4) | 47.9 (37.5–59.0) | −0.4 (−7.6 to 7.0) | 0.79 |
115 exposed, 68 unexposed. 3 months: 76 exposed, 41 unexposed. Note Hodges–Lehmann median differences have been used which are based on the Hodges–Lehmann estimate of the sample median and not the true median, which explains the discrepancy between the true median difference and the Hodges–Lehmann median difference estimate quoted.
CRP, C-reactive protein; HNE, human neutrophil elastase; HCMV, human cytomegalovirus; SLPI, secretory leucocyte protease inhibitor; TGFβ1, transforming growth factor β1.